PUBLIC COMPANY
saveEmalex Biosciences Inc
updated 15d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder
- phase3Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
- phase3A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
- phase1Food-effect Study of Ecopipam Pharmacokinetics
- phase1Drug Interaction Study
- phase2Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
- phase3Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
- phase1Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam
🐶 Hiring Signal
News
- STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and moreAstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spendingstat · 3mo ago
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that